Brief: Neovacs To Present Preclinical Results Of IL-4 / IL-13 Kinoid At Keystone Congress

Neovacs SA

21/03/2019 06:36

March 21 (Reuters) - NEOVACS SA  ALNEV.PA :
    * NEOVACS TO PRESENT THE PRECLINICAL RESULTS OF ITS
THERAPEUTIC
VACCINE CANDIDATE IL-4 / IL-13 KINOID AT KEYSTONE CONGRESS
    * WORK SHOWED THAT A TREATMENT WITH IL-4 / IL-13 KINOID
ENHANCED
PRODUCTION OF POLYCLONAL ANTIBODIES WHICH NEUTRALIZED TWO
TARGETED CYTOKINES IL-4 AND IL-13

Source text for Eikon:  ID:nGNE6BNZCN 
Further company coverage:  ALNEV.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))